The Nithya treatment is primarily aimed at restoring the skin's natural density and elasticity and visibly rejuvenating it.
Nithya is an innovative collagen therapy that involves intradermal injection of purified type I collagen to stimulate regenerative processes in the skin and stimulate the production of new collagen fibers. The product used in the treatment is derived from horse collagen, which is fully biocompatible and safe for human use, and when administered promotes tissue regeneration and improves firmness and elasticity.
The Nithya treatment is primarily aimed at restoring the skin's natural density and elasticity and visibly rejuvenating it. Collagen therapy helps reduce wrinkles, improves skin tone, promotes self-regeneration processes and produces an overall improvement in skin quality, especially in areas such as the face, neck and décolleté.
Eyelid plasty is a surgical procedure that significantly affects the aesthetics of the face and the well-being of the patient.
Side effects from the Nithya procedure are rare and may include:
All these symptoms usually disappear within 2-3 days.
The Nithya collagen therapy procedure is performed in an outpatient setting. After cleansing the skin and applying local anesthesia in the form of a cream, the doctor or cosmetologist administers the product with a thin needle into selected layers of the skin (mainly into the dermis or subcutis). The whole procedure takes about 30-45 minutes.
Immediately after the procedure, the skin may be slightly red and swollen, but the patient can return to daily activities the same day.
Article verified by lek. Aleksandra Jagielska. Information is for reference only and is not a substitute for medical consultation.
1.Anti-Age Activity and Tolerance Evaluation of Collagen Micro-Injection Treatment Associated to Topical Application of a Cosmetic Formulation (Sparavigna A. et al., 2017)
2.An Update on the Clinical Efficacy and Safety of Collagen-Based Injectables for Aesthetic and Regenerative Medicine Applications (Salvatore L. et al., 2023)